Type 2 Diabetes MellitusPhase 3Eluminate-2NCT07662213

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

A Phase 3 study testing Elecoglipron and Semaglutide in people with Type 2 Diabetes Mellitus, run by AstraZeneca at 210 sites in 15 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s). Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Type 2 Diabetes Mellitus
What is being tested?: Elecoglipron and Semaglutide
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 1,200 participants
Where: 210 sitesin 15 countries
Study dates: 6 Jul 2026to 23 May 2028
Phase: Phase 3
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors
Body mass index (BMI) of ≥ 23 kg/m2 at screening
Stable body weight (self-reported or documented) for 90 days prior to screening

Who cannot join

Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis
Severe congestive heart failure (NYHA IV)
History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Trial locations and contacts

210 sites in 15 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

210 sites in 15 countries

United States65 sites, 65 recruiting

Research Site
Albuquerque, New Mexico, 87112
Not yet recruiting
Research Site
Ames, Iowa, 50010
Recruiting
Research Site
Birmingham, Alabama, 35205
Not yet recruiting
Research Site
Bountiful, Utah, 84010
Not yet recruiting
Research Site
Bowling Green, Kentucky, 42101
Not yet recruiting
Research Site
Bridgeport, Connecticut, 06606
Not yet recruiting
Research Site
Columbus, Ohio, 43215
Not yet recruiting
Research Site
Covina, California, 91723
Not yet recruiting
Research Site
Crystal River, Florida, 34429
Not yet recruiting
Research Site
Dallas, Texas, 75390
Not yet recruiting
Research Site
Durham, North Carolina, 27701
Not yet recruiting
Research Site
Encinitas, California, 92024
Recruiting
Research Site
Evansville, Indiana, 47710
Not yet recruiting
Research Site
Falls Church, Virginia, 22042
Not yet recruiting
Research Site
Feasterville-Trevose, Pennsylvania, 19053
Not yet recruiting
Research Site
Garden Grove, California, 92844
Not yet recruiting
Research Site
Henderson, Nevada, 89052
Recruiting
Research Site
Hollywood, Florida, 33021
Not yet recruiting
Research Site
Houston, Texas, 77004
Recruiting
Research Site
Houston, Texas, 77040
Not yet recruiting
Research Site
Houston, Texas, 77079
Not yet recruiting
Research Site
Idaho Falls, Idaho, 83404
Not yet recruiting
Research Site
Jacksonville, Florida, 32209
Not yet recruiting
Research Site
Jefferson City, Missouri, 65109
Not yet recruiting
Research Site
Kansas City, Missouri, 64114
Not yet recruiting
Research Site
Katy, Texas, 77450
Not yet recruiting
Research Site
Lake City, Florida, 32055
Recruiting
Research Site
Las Vegas, Nevada, 89128
Not yet recruiting
Research Site
Leesburg, Florida, 34748
Recruiting
Research Site
Lilburn, Georgia, 30047
Not yet recruiting
Research Site
Loma Linda, California, 92354
Not yet recruiting
Research Site
Long Beach, California, 90807
Not yet recruiting
Research Site
Melrose Park, Illinois, 60160
Not yet recruiting
Research Site
Memphis, Tennessee, 38119
Not yet recruiting
Research Site
Mesa, Arizona, 85213
Not yet recruiting
Research Site
Minneapolis, Minnesota, 55416
Not yet recruiting
Research Site
Morehead City, North Carolina, 28557
Recruiting
Research Site
Morgantown, West Virginia, 26505
Not yet recruiting
Research Site
Morristown, Tennessee, 37813
Not yet recruiting
Research Site
Myrtle Beach, South Carolina, 29572
Not yet recruiting
Research Site
Norfolk, Virginia, 23502
Not yet recruiting
Research Site
North Charleston, South Carolina, 29405
Not yet recruiting
Research Site
Oklahoma City, Oklahoma, 73134
Not yet recruiting
Research Site
Omaha, Nebraska, 68114
Not yet recruiting
Research Site
Orlando, Florida, 32806
Not yet recruiting
Research Site
Philadelphia, Pennsylvania, 19114
Not yet recruiting
Research Site
Phoenix, Arizona, 85016
Recruiting
Research Site
Pomona, California, 91768
Recruiting
Research Site
Raleigh, North Carolina, 27612
Not yet recruiting
Research Site
Renton, Washington, 98057
Not yet recruiting
Research Site
Rockville, Maryland, 20852
Not yet recruiting
Research Site
Rockville, Maryland, 20852
Recruiting
Research Site
Sacramento, California, 95821
Recruiting
Research Site
Salt Lake City, Utah, 84124
Not yet recruiting
Research Site
San Antonio, Texas, 78229
Not yet recruiting
Research Site
San Antonio, Texas, 78231
Not yet recruiting
Research Site
Seattle, Washington, 98104
Not yet recruiting
Research Site
Seattle, Washington, 98105
Not yet recruiting
Research Site
Southfield, Michigan, 48076
Not yet recruiting
Research Site
Statesville, North Carolina, 28625
Not yet recruiting
Research Site
Sugar Land, Texas, 77478
Recruiting
Research Site
Tempe, Arizona, 85281
Not yet recruiting
Research Site
Weslaco, Texas, 78596
Not yet recruiting
Research Site
Wichita, Kansas, 67226
Not yet recruiting
Research Site
Wilmington, North Carolina, 28403
Recruiting

Other trials in United States

Germany19 sites, 17 recruiting

Research Site
Bad Oeynhausen, 32545
Not yet recruiting
Research Site
Berlin, 13597
Recruiting
Research Site
Chemnitz, 09116
Not yet recruiting
Research Site
Damme, 49401
Not yet recruiting
Research Site
Duisburg, 47051
Recruiting
Research Site
Elsterwerda, 04910
Not yet recruiting
Research Site
Erlangen, 91054
Recruiting
Research Site
Essen, 45359
Withdrawn
Research Site
Falkensee, 14612
Recruiting
Research Site
Gladbeck, 45968
Recruiting
Research Site
Hamburg, 21109
Recruiting
Research Site
Hamburg, 22607
Recruiting
Research Site
Leipzig, 04249
Recruiting
Research Site
Mannheim, 68167
Withdrawn
Research Site
Münster, 48145
Recruiting
Research Site
Oldenburg, 23758
Recruiting
Research Site
Pirna, 01796
Not yet recruiting
Research Site
Sankt Ingbert, 66386
Not yet recruiting
Research Site
Wangen, 88239
Recruiting

Other trials in Germany

Japan16 sites, 16 recruiting

Research Site
Asahikawa-shi, 070-8530
Recruiting
Research Site
Chūōku, 103-0002
Recruiting
Research Site
Kamakura-shi, 247-0056
Recruiting
Research Site
Koga-shi, 306-0232
Recruiting
Research Site
Kumamoto, 862-0976
Not yet recruiting
Research Site
Mitaka-shi, 181-0013
Recruiting
Research Site
Mito, 310-0826
Recruiting
Research Site
Miyazaki, 880-0034
Recruiting
Research Site
Nagoya, 467-8602
Recruiting
Research Site
Nagoya, 468-0009
Recruiting
Research Site
Naka, 311-0113
Recruiting
Research Site
Naka, 311-0133
Recruiting
Research Site
Nishinomiya-shi, 663-8113
Recruiting
Research Site
Osaka, 558-8558
Not yet recruiting
Research Site
Sapporo, 062-0007
Not yet recruiting
Research Site
Takamatsu, 760-0018
Recruiting

Other trials in Japan

China15 sites, 15 recruiting

Research Site
Changsha, 410013
Not yet recruiting
Research Site
Changsha, 410015
Not yet recruiting
Research Site
Hefei, 230000
Not yet recruiting
Research Site
Hefei, 230601
Not yet recruiting
Research Site
Huai'an, 223005
Not yet recruiting
Research Site
Langfang, 065000
Not yet recruiting
Research Site
Liangyugang, 222002
Recruiting
Research Site
Luoyang, 471009
Not yet recruiting
Research Site
Nanjing, 2100008
Recruiting
Research Site
Nanyang, 473009
Not yet recruiting
Research Site
Pinggu, 101200
Not yet recruiting
Research Site
Pingxiang, 337055
Not yet recruiting
Research Site
Shijiazhuang, 050000
Not yet recruiting
Research Site
Tianjin, 300134
Recruiting
Research Site
Yueyang, 414000
Not yet recruiting

Other trials in China

United Kingdom12 sites, 11 recruiting

Research Site
Aberdeen, AB25 2ZN
Recruiting
Research Site
Addlestone, KT15 2BH
Not yet recruiting
Research Site
Banbury, OX16 9AD
Recruiting
Research Site
Bristol, BS34 5TF
Recruiting
Research Site
Bristol, BS34 6BQ
Recruiting
Research Site
Edinburgh, EH4 2XU
Recruiting
Research Site
Hounslow, TW3 3LN
Recruiting
Research Site
Penzance, TR18 3DX
Recruiting
Research Site
Poole, BH16 5PW
Recruiting
Research Site
Soham, CB7 5JD
Recruiting
Research Site
Wansford, PE8 6PL
Withdrawn
Research Site
Yate, BS37 4AX
Recruiting

Other trials in United Kingdom

Canada10 sites, 10 recruiting

Research Site
Guelph, Ontario, N1H 1B1
Recruiting
Research Site
Montreal, Quebec, H4N 2W2
Recruiting
Research Site
Saint-Charles-Borromée, Quebec, J6E 2B4
Recruiting
Research Site
Sarnia, Ontario, N7T 4X3
Recruiting
Research Site
Scarborough Village, Ontario, M1R 0B1
Recruiting
Research Site
Stouffville, Ontario, L4A1H2
Recruiting
Research Site
Toronto, Ontario, M4G3E8
Recruiting
Research Site
Toronto, Ontario, M6G 1M2
Recruiting
Research Site
Toronto, Ontario, M9V 4B4
Recruiting
Research Site
Vancouver, British Columbia, V5Y 3W2
Recruiting

Other trials in Canada

South Korea10 sites, 10 recruiting

Research Site
Busan, 48108
Not yet recruiting
Research Site
Changwon-si, 51353
Not yet recruiting
Research Site
Daegu, 41404
Recruiting
Research Site
Daejeon, 35015
Recruiting
Research Site
Daejeon, 35233
Not yet recruiting
Research Site
Guri-si, 11923
Not yet recruiting
Research Site
Incheon, 21565
Recruiting
Research Site
Seoul, 05278
Recruiting
Research Site
Seoul, 06351
Recruiting
Research Site
Seoul, 3722
Not yet recruiting

Other trials in South Korea

Taiwan10 sites, 10 recruiting

Research Site
Changhua, 50006
Recruiting
Research Site
Kaohsiung City, 81362
Recruiting
Research Site
New Taipei City, 220
Recruiting
Research Site
Taichung, 40201
Recruiting
Research Site
Taichung, 40705
Recruiting
Research Site
Taichung, 433004
Recruiting
Research Site
Tainan, 704
Recruiting
Research Site
Taipei, 10002
Recruiting
Research Site
Taoyuan, 333
Recruiting
Research Site
Yung Kang City, 71044
Not yet recruiting

Other trials in Taiwan

Australia9 sites, 9 recruiting

Research Site
Botany, 2019
Recruiting
Research Site
East Toowoomba, 4350
Recruiting
Research Site
Fitzroy, 3065
Recruiting
Research Site
Heidelberg Heights, 3081
Recruiting
Research Site
Kingswood, 2747
Not yet recruiting
Research Site
Melbourne, 3004
Recruiting
Research Site
Parkville, 3050
Recruiting
Research Site
Penrith, 2750
Recruiting
Research Site
St Leonards, 2065
Recruiting

Other trials in Australia

Italy9 sites, 9 recruiting

Research Site
Bari, 70124
Not yet recruiting
Research Site
Bologna, 40138
Not yet recruiting
Research Site
Chieti, 66100
Recruiting
Research Site
Milan, 20132
Not yet recruiting
Research Site
Milan, 20138
Recruiting
Research Site
Modena, 41100
Not yet recruiting
Research Site
Naples, 80138
Not yet recruiting
Research Site
Roma, 00161
Recruiting
Research Site
Roma, 00168
Recruiting

Other trials in Italy

Hungary8 sites, 5 recruiting

Research Site
Budapest, 1036
Recruiting
Research Site
Budapest, 1089
Recruiting
Research Site
Budapest, 1132
Recruiting
Research Site
Debrecen, 4032
Recruiting
Research Site
Salgótarján, 3100
Withdrawn
Research Site
Szeged, 6725
Not yet recruiting
Research Site
Szolnok, 5000
Withdrawn
Research Site
Zalaegerszeg, 8900
Withdrawn

Other trials in Hungary

Poland8 sites, 8 recruiting

Research Site
Bialystok, 15-897
Recruiting
Research Site
Krakow, 31-261
Not yet recruiting
Research Site
Lodz, 90-338
Recruiting
Research Site
Lublin, 20-718
Not yet recruiting
Research Site
Poznan, 60-354
Recruiting
Research Site
Radom, 26-600
Recruiting
Research Site
Warsaw, 00-124
Recruiting
Research Site
Warsaw, 02-507
Recruiting

Other trials in Poland

Argentina7 sites, 7 recruiting

Research Site
Buenos Aires, C1120AAC
Recruiting
Research Site
Buenos Aires, C1425AGC
Recruiting
Research Site
Caba, C1128AAF
Recruiting
Research Site
Ciudad de Buenos Aires, C1094AAD
Recruiting
Research Site
Rosario, S2000CVD
Recruiting
Research Site
San Nicolás, B2900DMH
Not yet recruiting
Research Site
San Vicente, 5006
Recruiting

Other trials in Argentina

Brazil7 sites, 7 recruiting

Research Site
Brasília, 71625-009
Not yet recruiting
Research Site
Campinas, 13060-803
Not yet recruiting
Research Site
Curitiba, 80030-480
Not yet recruiting
Research Site
Natal, 59020-500
Not yet recruiting
Research Site
Porto Alegre, 90630-165
Not yet recruiting
Research Site
São José dos Campos, 12243-280
Not yet recruiting
Research Site
São Paulo, 04012-180
Not yet recruiting

Other trials in Brazil

Bulgaria5 sites, 5 recruiting

Research Site
Plovdiv, 4001
Recruiting
Research Site
Sofia, 1407
Recruiting
Research Site
Sofia, 1618
Recruiting
Research Site
Sofia, 1700
Recruiting
Research Site
Yambol, 8600
Recruiting

Other trials in Bulgaria

About this study

Official title: A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

Conditions: Type 2 Diabetes Mellitus
Being tested: Elecoglipron, Semaglutide
Medical subject headings: Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

ElecoglipronDrug
Elecoglipron is administered orally once daily.
SemaglutideDrug
Semaglutide is administered orally once daily.

Study groups in NCT07662213
Study group	Role	What they receive
Elecoglipron	Experimental	Participants will receive elecoglipron dose XX mg administered orally once daily. Receives: Drug: Elecoglipron
Semaglutide	Active comparator	Participants will receive semaglutide dose XX mg administered orally once daily. Receives: Drug: Semaglutide

What is being measured

The primary outcome is the main question the study is designed to answer.

Change from baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline to Week 52

Secondary outcomes (7)

Percent change from baseline to Week 52 in body weight
Measured: Baseline to Week 52
Change from baseline to Week 52 in body weight (kg)
Measured: Baseline to Week 52
Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52
Measured: Baseline to Week 52
Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52
Measured: Week 52
Achieved HbA1c < 7% (53 mmol/mol) at Week 52
Measured: Week 52
Achieved ≥ 5% weight loss from baseline at Week 52
Measured: Baseline to Week 52
Change from baseline to Week 52 in Systolic Blood Pressure (BP) and Diastolic BP
Measured: Baseline to Week 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

6 Jul 202623 May 2028

First posted23 Jun 2026
Study start6 Jul 2026
Primary completion23 May 2028 (estimated)
Study completion23 May 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Type 2 Diabetes MellitusStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Enrolment: 1,200 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07662213
Sponsor's protocol ID: D7261C00005
Other IDs: 2025-523933-24-00, 2025
Acronym: Eluminate-2
Status last verified: Oct 2026
First submitted: 18 Jun 2026
Last updated: 22 Oct 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Recruiting
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
Active, not recruiting
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
PreDiabetes, Diabetes Mellitus, Type 2
Not yet recruitingPhase 1/2
A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations
Cochlear Synaptopathy
Not yet recruitingPhase 1
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2

All Type 2 Diabetes Mellitus trials

Study at a glance

From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)
ClinicalTrials.gov ID: NCT07662213
Acronym / sponsor ID: Eluminate-2 / D7261C00005
Conditions: Type 2 Diabetes Mellitus
Phase: Phase 3
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 1,200 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 6 Jul 2026 (actual)
Primary completion: 23 May 2028 (estimated)
Study completion: 23 May 2028 (estimated)
First posted: 23 Jun 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: None (open label)
Number of arms: 2

Arm	Type	Receives
Elecoglipron	Experimental	Drug: ElecoglipronParticipants will receive elecoglipron dose XX mg administered orally once daily.
Semaglutide	Active comparator	Drug: SemaglutideParticipants will receive semaglutide dose XX mg administered orally once daily.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (6 listed)

Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening
T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s)
HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol)
Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors
Body mass index (BMI) of ≥ 23 kg/m2 at screening

Key exclusion criteria (7 listed)

Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying
History of acute or chronic pancreatitis

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
ElecoglipronElecoglipron is administered orally once daily.	Drug	Elecoglipron
SemaglutideSemaglutide is administered orally once daily.	Drug	Semaglutide

Primary outcome

Change from baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline to Week 52

7 secondary outcomes

Percent change from baseline to Week 52 in body weight
Time frame: Baseline to Week 52
Change from baseline to Week 52 in body weight (kg)
Time frame: Baseline to Week 52
Achieved ≥ 5% weight loss from baseline at Week 52 and achieved HbA1c < 7% (53 mmol/mol) at Week 52
Time frame: Baseline to Week 52
Achieved HbA1c ≤ 6.5% (48 mmol/mol) at Week 52
Time frame: Week 52
Achieved HbA1c < 7% (53 mmol/mol) at Week 52
Time frame: Week 52
Achieved ≥ 5% weight loss from baseline at Week 52
Time frame: Baseline to Week 52
Change from baseline to Week 52 in Systolic Blood Pressure (BP) and Diastolic BP
Time frame: Baseline to Week 52

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for Type 2 Diabetes Mellitus

Recruiting
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
Active, not recruiting
Metabolic and Inflammatory Outcomes of the Ketogenic Diet Comparing Saturated and Unsaturated Fat Sources
PreDiabetes, Diabetes Mellitus, Type 2
Not yet recruitingPhase 1/2
A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have Difficulty Understanding Speech in Noisy Situations
Cochlear Synaptopathy
Not yet recruitingPhase 1
A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

210 sites in 15 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Elecoglipron and Semaglutide in people with Type 2 Diabetes Mellitus, run by AstraZeneca at 210 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 210 sites in United States, Germany, Japan, China, United Kingdom and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in Hemoglobin A1c (HbA1c) (time frame: Baseline to Week 52). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07662213.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.